{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T19:00:52Z","timestamp":1771009252423,"version":"3.50.1"},"reference-count":13,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"44","license":[{"start":{"date-parts":[[2018,11,1]],"date-time":"2018-11-01T00:00:00Z","timestamp":1541030400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,11]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Rationale:<\/jats:title>\n            <jats:p>Subcutaneous immunoglobulin administration facilitated by recombinant human hyaluronidase is a new mode of immunoglobulin replacement. It has been approved for treatment in primary and secondary antibody immunodeficiency. To date, it has not been reported in the literature as therapy of choice during pregnancy.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Patient concerns:<\/jats:title>\n            <jats:p>We report a 31-year-old woman with common variable immunodeficiency (CVID) followed during her first pregnancy.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Diagnoses:<\/jats:title>\n            <jats:p>The patient had a history of increased susceptibility to infections and autoimmune phenomena. From diagnosis at the age 29, she received IVIg replacement with partial response to treatment. Due to medical indications and lack of venous access, we had to search for another mode of application. The patient refused traditional, weekly conventional subcutaneous immunoglobulin (SCIg) administration.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Interventions:<\/jats:title>\n            <jats:p>Immunoglobulin replacement therapy was successfully continued during pregnancy after the IV route was replaced with subcutaneous administration facilitated by recombinant human hyaluronidase. The frequency of infusions was every 3\u20134 weeks.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Outcomes:<\/jats:title>\n            <jats:p>The treatment was effective and well tolerated by the patient who continued it after delivery. Dosage and the schedule of infusions provided sufficient immunoglobulin G (IgG) levels for the newborn baby.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Lessons:<\/jats:title>\n            <jats:p>The presented CVID case illustrates that the selection of the mode of immunoglobulin administration has to be a shared decision, which considers both patient preferences and medical needs. This approach is especially important for the pregnancy period. The case shows that the switch from IVIg to fSCIg can be a management option during pregnancy.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/md.0000000000012804","type":"journal-article","created":{"date-parts":[[2018,10,31]],"date-time":"2018-10-31T23:41:29Z","timestamp":1541029289000},"page":"e12804","source":"Crossref","is-referenced-by-count":4,"title":["A case report of pregnancy in a patient with common variable immunodeficiency emphasizing the need for personalized immunoglobulin replacement"],"prefix":"10.1097","volume":"97","author":[{"given":"Ewa","family":"Wi\u0119sik-Szewczyk","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karina","family":"Jahnz-R\u00f3\u017cyk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-20230914","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1007\/s10875-014-0123-3","article-title":"Fertility, pregnancies and outcomes reported by females with common variable immune deficiency and hypogammaglobulinemia: results from an internet-based survey","volume":"35","author":"Gundlapalli","year":"2015","journal-title":"J Clin Immunol"},{"key":"R2-20230914","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1111\/j.1365-2249.2009.04027.x","article-title":"Subcutaneous immunoglobulin: opportunities and outlook","volume":"1","author":"Misbah","year":"2009","journal-title":"Clin Exp Immunol"},{"key":"R3-20230914","doi-asserted-by":"crossref","first-page":"105","DOI":"10.2165\/00063030-200721020-00005","article-title":"Immunoglobulin treatment for primary antibody deficiencies: advantages of the subcuteneous route","volume":"21","author":"Garduf","year":"2007","journal-title":"BioDrugs"},{"key":"R4-20230914","doi-asserted-by":"crossref","first-page":"553","DOI":"10.2217\/imt.14.34","article-title":"Overview of recombinant human hyaluronidase facilitated subcutaneous infusion of IgG in primary immunodeficiencies","volume":"6","author":"Wasserman","year":"2014","journal-title":"Immunotherapy"},{"key":"R5-20230914","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1016\/j.jaci.2012.06.021","article-title":"Recombinant human hyaluronidase-facilitated subcutaneous infusion of human immunoglobulins for primary immunodeficiency","volume":"130","author":"Wasserman","year":"2012","journal-title":"J Allergy Clin Immunol"},{"key":"R6-20230914","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1111\/cei.12694","article-title":"Facilitated subcutaneous immunoglobulin (fSCIg) therapy \u2013 practical considerations","volume":"182","author":"Ponsford","year":"2015","journal-title":"Clin Exp Immnol"},{"key":"R7-20230914","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/0002-9343(84)90323-1","article-title":"Use of intravenous immune globulin in pregnant women with common variable hypogammaglobulinemia","volume":"30","author":"Sorensen","year":"1984","journal-title":"Am J Med"},{"key":"R8-20230914","first-page":"39S","article-title":"Intravenous immunoglobulin in pregnancy","volume":"66","author":"Smith","year":"1985","journal-title":"Obstet Gyncol"},{"key":"R9-20230914","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1023\/A:1011051704960","article-title":"Rapid subcutaneous IgG replacement therapy at home for pregnant immunodeficient women","volume":"21","author":"Gardulf","year":"2001","journal-title":"J Clin Immunol"},{"key":"R10-20230914","doi-asserted-by":"crossref","first-page":"2824","DOI":"10.1001\/jama.1982.03320450058038","article-title":"High-dose immunoglobulin replacement therapy by slow subcutaneous infusion during pregnancy","volume":"28","author":"Berger","year":"1982","journal-title":"JAMA"},{"key":"R11-20230914","first-page":"1","article-title":"Intravenous immunoglobulin (IVIG) efficiency in woman with common variable immunodeficiency decreases significantly during pregnancy","volume":"3","author":"Egawa","year":"2018","journal-title":"J Matern Fetal Neonatal Med"},{"key":"R12-20230914","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1002\/ccr3.692","article-title":"Management of common variable immunodeficiency by subcutaneous IgG self-administration during pregnancy- a case report","volume":"28","author":"Marasco","year":"2017","journal-title":"Clin Case Rep"},{"key":"R13-20230914","first-page":"pii: bcr2012007594","article-title":"Management of a pregnant woman with common variable immunodeficiency and previous reactions to intravenous IgG administration","volume":"2012","author":"Danieli","year":"2012","journal-title":"J Clin Immunol"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00005792-201811020-00012","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,14]],"date-time":"2023-09-14T18:18:38Z","timestamp":1694715518000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00005792-201811020-00012"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11]]},"references-count":13,"journal-issue":{"issue":"44","published-print":{"date-parts":[[2018]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000012804","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,11]]}}}